Brooks Laboratories Share Price

    NSE
    149
    +0.33 (0.67%)
    BROOKS • 25 Jun, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    73.62%

    3Y Annualised Return

    20.49%

    5Y Annualised Return

    39.17%

    The current prices are delayed, login or Open Demat Account for live prices.

    Brooks Laboratories Stock Performance

    1W Return10.39
    1Y Return77.09
    Today's Low151.64
    Prev. Close148.67
    Mkt Cap (Cr.)437.94
    1M Return18.45
    3Y Return85.33
    52-Week High198.86
    Open151.64
    PE Ratio139.57
    6M Return-16.71
    Today's High151.64
    52-Week Low82
    Face Value10

    Brooks Laboratories Company background

    Founded in: 2002
    Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. Brooks Laboratories is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a worlds largest dedicated EU certified plant at Vadodara.In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (RD) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal Rajesh Mahajan.In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS IAF.In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.On 7 March 2017, Brooks Laboratories world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line.The Company started production and sales at its manufacturing facility in Vadodara in 201920.

    As of 25 Jun, 2025, Brooks Laboratories share price is ₹151.6. The stock opened at ₹151.6 and had closed at ₹148.7 the previous day. During today’s trading session, Brooks Laboratories share price moved between ₹151.64 and ₹151.64, with an average price for the day of ₹151.64. Over the last 52 weeks, the stock has recorded a low of ₹82.00 and a high of ₹198.86. In terms of performance, Brooks Laboratories share price has declined by 16.7% over the past six months and has increased by 73.62% over the last year.

    Read More
    Brooks Laboratories SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹96,13,939 (+47.91%)
    Daily SIP of 25,000 would have become 96,13,939 in 1 year with a gain of 31,13,939 (+47.91%)
    View details of Market Depth

    Brooks Laboratories Fundamental

    Market Cap (in crs)

    437.94

    Face Value

    10

    Turnover (in lacs)

    5.82

    Key Metrics

    Qtr Change %
    84.93% Gain from 52W Low
    22.5
    Dividend yield 1yr %
    0

    Brooks Laboratories Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Brooks Laboratories Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    23.32 Cr
    38.45 Cr
    20.79 Cr
    17.93 Cr
    17.72 Cr
    Brooks Laboratories Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    83.44 Cr
    80.44 Cr
    63.41 Cr
    91.99 Cr
    77.98 Cr
    Brooks Laboratories Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1.34 Cr
    0.7 Cr
    0.96 Cr
    -0.21 Cr
    0.3 Cr
    Brooks Laboratories Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    3.02 Cr
    1.53 Cr
    -27.74 Cr
    -19.31 Cr
    -19.37 Cr

    Brooks Laboratories Result Highlights

    • Brooks Laboratories Ltd reported a 52.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 45.5%.

    • Its expenses for the quarter were down by 52.2% QoQ and up 35.4% YoY.

    • The net profit increased 110.3% QoQ and increased 123.5% YoY.

    • The earnings per share (EPS) of Brooks Laboratories Ltd declined at 3.8 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Brooks Laboratories

    Promoter
    52.6%
    Mutual Funds
    9.9%
    Domestic Institutions
    10.4%
    Public
    37%
    Promoter
    59.1%
    Mutual Funds
    3.9%
    Domestic Institutions
    3.9%
    Public
    37.1%
    Promoter
    63.6%
    Mutual Funds
    3.9%
    Domestic Institutions
    3.9%
    Public
    32.5%
    Promoter
    63.6%
    Mutual Funds
    3.9%
    Domestic Institutions
    3.9%
    Public
    32.6%
    Promoter
    63.6%
    Mutual Funds
    3.9%
    Domestic Institutions
    3.9%
    Public
    32.6%
    Promoter
    63.6%
    Mutual Funds
    3.9%
    Domestic Institutions
    3.9%
    Public
    32.6%

    Brooks Laboratories Technical Analysis

    Moving Averages Analysis
    149
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    144.90
    10Day EMA
    143.50
    12Day EMA
    143.00
    20Day EMA
    141.20
    26Day EMA
    140.20
    50Day EMA
    137.40
    100Day EMA
    136.00
    200Day EMA
    133.80
    5Day SMA
    143.00
    10Day SMA
    144.50
    20Day SMA
    139.40
    30Day SMA
    138.50
    50Day SMA
    136.50
    100Day SMA
    128.90
    150Day SMA
    140.00
    200Day SMA
    140.50
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    7967 Rs
    7967 Rs
    Week Rs
    17928 Rs
    17928 Rs
    Month Rs
    32327 Rs
    32327 Rs
    148.67
    Pivot
    Resistance
    First Resistance
    148.67
    Second Resistance
    148.67
    Third Resistance
    148.67
    Support
    First Support
    148.67
    Second support
    148.67
    Third Support
    148.67
    Relative Strength Index
    61.55
    Money Flow Index
    91.57
    MACD
    2.88
    MACD Signal
    2.56
    Average True Range
    4.71
    Average Directional Index
    17.31
    Rate of Change (21)
    16.13
    Rate of Change (125)
    -21.58
    Name
    Holding Percent
    Quant Mutual Fund - Quant Business Cycle Fund
    9.9

    Brooks Laboratories Latest News

    25 JUN 2025 | Wednesday

    Brooks Laboratories Ltd - 533543 - Closure of Trading Window

    29 MAY 2025 | Thursday

    Brooks Laboratories Ltd - 533543 - Compliances-Reg.24(A)-Annual Secretarial Compliance

    29 MAY 2025 | Thursday

    Brooks Laboratories Ltd - 533543 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    View More

    Brooks Laboratories Share Price FAQs

    Brooks Laboratories share price is ₹149 in NSE and ₹148.05 in BSE as on 11/7/2025.

    Brooks Laboratories share price in the past 1-year return was 77.08. The Brooks Laboratories share hit a 1-year low of Rs. 82 and a 1-year high of Rs. 198.86.

    The market cap of Brooks Laboratories is Rs. 437.94 Cr. as of 11/7/2025.

    The PE ratios of Brooks Laboratories is 139.57 as of 11/7/2025.

    The PB ratios of Brooks Laboratories is 3.71 as of 11/7/2025

    The Mutual Fund Shareholding in Brooks Laboratories was 9.9% at the end of 11/7/2025.

    You can easily buy Brooks Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Brooks Laboratories share price is ₹198.86 and ₹82 as of 11/7/2025.

    Please be aware that Brooks Laboratories stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.57
    -0.40 (-0.61%)
    136.00
    -1.13 (-0.82%)
    690.05
    -5.55 (-0.80%)
    2,577.30
    -3.70 (-0.14%)
    161.82
    -7.82 (-4.61%)
    383.00
    -1.70 (-0.44%)
    160.16
    -0.50 (-0.31%)
    263.55
    +0.70 (+0.27%)
    409.95
    -3.55 (-0.86%)
    398.65
    -1.25 (-0.31%)
    Top Gainers
    2,522.50
    +114.10 (+4.74%)
    1,826.30
    +16.10 (+0.89%)
    2,422.60
    +21.20 (+0.88%)
    1,673.60
    +11.10 (+0.67%)
    1,171.40
    +7.10 (+0.61%)
    Top Losers
    3,290.20
    -91.80 (-2.71%)
    7,177.50
    -181.50 (-2.47%)
    258.55
    -6.50 (-2.45%)
    3,087.60
    -74.80 (-2.37%)
    8,097.50
    -187.50 (-2.26%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -